Back to Report Store Home

Global Respiratory Drugs Market to 2023 – A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers

  • Published: Sep-2017
  • Report Code: GBIHC453MR
  • Report Format: pdf

Description

List of Tables

Table 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology, 2017 24

Table 2: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 0–4 Years of Age 29

Table 3: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 5–11 Years of Age 29

Table 4: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Youths of 12 Years or More and Adults 30

Table 5: Respiratory Disorders Therapeutics Market, Global, COPD Disease Severity, 2016 31

Table 6: Respiratory Disorders Therapeutics Market, Global, COPD Patient Risk Categories, 2016 32

Table 7: Respiratory Disorders Therapeutics Market, Global, IPF Severity Classification, 2016 32

Table 8: Respiratory Disorders Therapeutics Market, Global, CF Severity Classification, 2016 34

Table 9: Respiratory Disorders Therapeutics Market, Global, COPD Treatment Algorithm, 2016 37

Table 10: Respiratory Disorders Therapeutics Market, Global, CF Treatment Plan, 2016 39

Table 11: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Advair, 2017 43

Table 12: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Symbicort, 2017 45

Table 13: Respiratory Disorders Therapeutics Market 47

Table 14: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Xolair, 2017 49

Table 15: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Ventolin, 2017 50

Table 16: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Pulmicort, 2017 51

Table 17: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Orkambi, 2017 52

Table 18: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Relvar/Breo Ellipta, 2017 54

Table 19: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Singulair, 2017 55

Table 20: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Esbriet, 2017 57

Table 21: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Kalydeco, 2017 59

Table 22: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2016–2023 93

Table 23: Respiratory Disorders Therapeutics Market, Global, Usage of Generics Across Key Indications, 2017 96

Table 24: Respiratory Disorders Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006–2017 126

Table 25: Respiratory Disorders Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006–2017 136

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards